An AICD-based functional screen to identify APP metabolism regulators by Khandelwal, Preeti J et al.
 
An AICD-based functional screen to identify APP metabolism
regulators
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zhang, Can, Preeti J. Khandelwal, Ranjita Chakraborty, Trinna L.
Cuellar, Srikant Sarangi, Shyam A. Patel, Christopher P.
Cosentino, Michael O'Connor, Jeremy C. Lee, Rudolph E. Tanzi,
and Aleister J. Saunders.  2007.  An AICD-based functional screen
to identify APP metabolism regulators.  Molecular
Neurodegeneration 2: 15.
Published Version doi://10.1186/1750-1326-2-15
Accessed February 19, 2015 7:33:44 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4688061
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 19
(page number not for citation purposes)
Molecular Neurodegeneration
Open Access Research article
An AICD-based functional screen to identify APP metabolism 
regulators
Can Zhang†1, Preeti J Khandelwal†1, Ranjita Chakraborty1, Trinna L Cuellar1, 
Srikant Sarangi1, Shyam A Patel1, Christopher P Cosentino1, 
Michael O'Connor1, Jeremy C Lee1, Rudolph E Tanzi2 and 
Aleister J Saunders*1,3
Address: 1Department of Bioscience & Biotechnology, Drexel University, Philadelphia, PA, USA, 2Genetics and Aging Research Unit, MassGeneral 
Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
Charlestown, MA, USA and 3Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA
Email: Can Zhang - cz33@drexel.edu; Preeti J Khandelwal - pjk25@drexel.edu; Ranjita Chakraborty - rm3282@drexel.edu; 
Trinna L Cuellar - tcuellar@diabetes.ucsf.edu; Srikant Sarangi - smg36@drexel.edu; Shyam A Patel - sap42@drexel.edu; 
Christopher P Cosentino - nimblejak@aol.com; Michael O'Connor - oconnomp@drexel.edu; Jeremy C Lee - jl46@drexel.edu; 
Rudolph E Tanzi - tanzi@helix.mgh.harvard.edu; Aleister J Saunders* - Aleister.Saunders@drexel.edu
* Corresponding author    †Equal contributors
Abstract
Background: A central event in Alzheimer's disease (AD) is the regulated intramembraneous
proteolysis of the β-amyloid precursor protein (APP), to generate the β-amyloid (Aβ) peptide and
the APP intracellular domain (AICD). Aβ is the major component of amyloid plaques and AICD
displays transcriptional activation properties. We have taken advantage of AICD transactivation
properties to develop a genetic screen to identify regulators of APP metabolism. This screen relies
on an APP-Gal4 fusion protein, which upon normal proteolysis, produces AICD-Gal4. Production
of AICD-Gal4 induces Gal4-UAS driven luciferase expression. Therefore, when regulators of APP
metabolism are modulated, luciferase expression is altered.
Results: To validate this experimental approach we modulated α-, β-, and γ-secretase levels and
activities. Changes in AICD-Gal4 levels as measured by Western blot analysis were strongly and
significantly correlated to the observed changes in AICD-Gal4 mediated luciferase activity. To
determine if a known regulator of APP trafficking/maturation and Presenilin1 endoproteolysis could
be detected using the AICD-Gal4 mediated luciferase assay, we knocked-down Ubiquilin 1 and
observed decreased luciferase activity. We confirmed that Ubiquilin 1 modulated AICD-Gal4 levels
by Western blot analysis and also observed that Ubiquilin 1 modulated total APP levels, the ratio
of mature to immature APP, as well as PS1 endoproteolysis.
Conclusion: Taken together, we have shown that this screen can identify known APP metabolism
regulators that control proteolysis, intracellular trafficking, maturation and levels of APP and its
proteolytic products. We demonstrate for the first time that Ubiquilin 1 regulates APP metabolism
in the human neuroblastoma cell line, SH-SY5Y.
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Background
Alzheimer's disease (AD) is characterized by significant
accumulation of cerebral amyloid plaques and intraneu-
ronal neurofibrillary tangles. Amyloid plaques are com-
posed mainly of the β-amyloid peptide (Aβ). Aβ is a
normal product of amyloid precursor protein (APP)
metabolism. Several genes have been identified encoding
enzymes that directly metabolize APP to generate Aβ;
however, it is not fully understood how APP metabolism
is regulated. Here we describe and validate a novel exper-
imental approach for identifying genes encoding regula-
tors of APP metabolism.
Aβ is generated by the successive proteolytic processing of
APP, a process referred to as regulated intramembrane
proteolysis (RIP) [1-3]. RIP occurs when a transmembrane
protein is cleaved within the transmembrane domain,
releasing a cytoplasmic fragment that can activate gene
expression in the nucleus [1]. RIP requires two cleavage
events; the first, outside the membrane, often in response
to ligand binding, can trigger the second, intramembrane-
ous, cleavage. RIP liberates small, intracellular protein
domains that are involved in nuclear signaling processes
[1,2]. Therefore, regulation of RIP is critical for controlling
nuclear signaling. Identifying the regulatory mechanisms
controlling these proteolytic steps is important for a fuller
understanding of these processes.
APP is a type I transmembrane glycoprotein and is sug-
gested to function in neuroprotection, synaptic transmis-
sion, signal transduction, and axonal transport [4,5].
Upon being synthesized, APP undergoes maturation in
the protein secretory pathway. APP is N-glycosylated in
the ER and cis-Golgi followed by O-glycosylation in
medial- and trans-Golgi. RIP of APP can occur via two
alternative routes: amyloidogenic and non-amyloidog-
enic. In amyloidogenic processing, APP undergoes
sequential cleavage by β-secretase (BACE) and γ-secretase
to generate Aβ [6]. BACE cleavage occurs in the APP extra-
cellular domain to produce a soluble extracellular frag-
ment called sAPPβ and a membrane associated, 99-
residue C-terminal fragment called C99 [7] The C99 frag-
ment is a substrate for subsequent cleavage by the γ-secre-
tase complex [8,9]. The active γ-secretase complex is
composed of the amino- and carboxy-terminal fragments
of presenilin1 (PS1), a highly glycosylated form of nicas-
trin (NCSTN), Aph1α and Pen-2 [8,9]. The amino- and
carboxy-terminal fragments of PS1 (~27 and ~17 kDa
respectively) are derived by endoproteolytic cleavage of
the inactive, full length PS1 protein within the large
hydrophilic loop that spans between transmembrane hel-
ices 6 and 7 and are thought to interact with each other
[10]. The products of γ-secretase cleavage are the cytoplas-
mic APP Intracellular Domain (AICD) fragment and Aβ
peptides of varying length, mainly 40 and 42 residues
long [11-13]. In non-amyloidogenic processing, the ini-
tial extracellular cleavage of APP is catalyzed by one of a
group of proteases termed α-secretases. These enzymes
include ADAM9, ADAM10, and ADAM17 (TACE). α-
secretase cleavage produces a soluble extracellular frag-
ment called sAPPα and a membrane associated, 83-resi-
due C-terminal fragment called C83. This C83 fragment is
then cleaved by the γ-secretase complex to produce AICD
and a p3 peptide, which is not involved in amyloidogen-
esis [6].
A common feature of RIP processing is the liberation of an
intracellular protein domain that initiates nuclear signal-
ing [1,2]. In the case of APP processing, nuclear signaling
can be initiated by the production of the intracellular
AICD fragment. Once generated by γ-secretase, the AICD
fragment can be stabilized and transported to the nucleus
by the cytoplasmic adaptor protein Fe65 [14,15]. Upon
entering the nucleus the AICD/Fe65 complex can form a
tripartite, transcriptionally active complex with the his-
tone acetyltransferase Tip60 [16,17]. Consistent with this
model, cells concomitantly over-expressing an APP-Gal4-
DNA binding domain fusion protein and Fe65, and carry-
ing a Gal4 UAS-driven reporter construct display a >2000
fold increase in reporter transcription compared to cells
over-expressing just the Gal4 DNA binding domain and
Fe65 [16]. This increase in transactivation activity is
dependent on Tip60 and can be abolished when the inter-
action between AICD and Fe65 is disrupted by mutagene-
sis of the AICD NPTY motif, the binding site for Fe65 [16].
However, these data do not rule out a possible effect of
full-length APP in inducing nuclear signaling. Indeed,
APP nuclear signaling can occur in the absence of γ-secre-
tase activity and therefore does not require the AICD frag-
ment [18]. The relative contribution of AICD-mediated
versus holo-APP mediated nuclear signaling is not clear at
this time [16-18].
The genomic targets of AICD- or APP-mediated nuclear
signaling are not clearly defined. APP, BACE, Tip60, GSK-
3β, Mn-SOD, KAI1, NEP and other genes have all been
reported to be targets of APP mediated transcriptional
activation [19-22]; however, there is a paucity of confirm-
atory reports [18]. At this time, the biological role of
AICD-mediated transactivation is not clear [20,23,24].
Despite this confusion, evidence suggests that defective
APP signaling is involved in AD pathogenesis [25-29].
Given the centrality of APP in AD, it is crucial to identify
regulators of APP metabolism, including, but not limited
to, APP proteolysis. Regulation of APP metabolism can
occur by numerous mechanisms, including regulation of
APP transcription, APP translation, APP maturation, intra-
cellular trafficking of full-length APP and APP cleavage
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Komano and colleagues have used a genetic screen to spe-
cifically identify regulators of γ-secretase activity [30], a
screen that will identify APP metabolism regulators that
act through multiple mechanisms is needed.
Here we describe a novel experimental approach to iden-
tify a variety of regulators of APP metabolism. We use an
AICD-Gal4 mediated luciferase expression assay as a gen-
eral reporter of APP metabolism in the human neuroblas-
toma cell lines, SH-SY5Y. To validate this assay, we
utilized pharmacologic agents, as well as forward and
reverse genetics, to modulate APP proteolysis, AICD traf-
ficking and AICD transactivation. To determine if regula-
tors of APP maturation and PS1 endoproteolysis also can
be detected with this screening approach, we knocked-
down Ubiquilin 1 and observed decreased AICD-Gal4
luciferase activity. Using Western blot analysis, we show
that Ubiquilin 1 controls APP levels, the ratio of mature to
immature APP, as well as presenilin1 endoproteolysis,
confirming the previously reported role of Ubiquilin 1 in
APP and presenilin1 metabolism in non-neuronal human
cell lines [31-34]. Taken together, our results validate the
use of the AICD-Gal4 mediated luciferase assay in combi-
nation with forward and reverse genetics as a screen to
identify APP metabolism regulators.
Results
Establishment of a functional assay to identify APP 
metabolism regulators
We utilized the APP-Gal4/Gal4-UAS luciferase reporter
system (Figure 1A) developed by Cao and Südhof [16].
We established this assay system in our laboratory by cre-
ating a SH-SY5Y, human neuroblastoma, cell line that sta-
bly expresses the assay components. Three different stable
cell lines have been generated; all stably carry a luciferase
reporter gene under the control of the Gal4-UAS (Gal4-
UAS luciferase). In addition to this reporter gene, one cell
line expresses the Gal4 DNA binding domain alone
(SY5Y-Gal4), the second cell line expresses APP695 fused
to the Gal4 DNA binding domain (SY5Y-APP-Gal4), and
the third cell line expresses a mutated version of APP695-
Gal4 (SY5Y-APP*-Gal4). This mutation in APP alters the
NPTY motif (P685A; Y687A) and disrupts Fe65 binding to
this site [16]. Once these cells were established, luciferase
assays were performed to determine the relative luciferase
activity of the cell lines (Figure 1B). SY5Y-APP-Gal4 cells
have a statistically significant (p < 0.01) ~20 fold increase
in luciferase activity compared to SY5Y cells expressing
either Gal4 or APP*-Gal4.
Pharmacologic modulation of α- and γ-secretase activity 
alters AICD-Gal4 mediated luciferase activity
To determine if monitoring AICD-Gal4 mediated luci-
ferase activity is a valid method to detect alterations in
APP metabolism, we used pharmacologic agents known
to modulate APP proteolytic processing and compared the
effects of these agents on levels of APP proteolytic prod-
ucts and AICD-Gal4 mediated luciferase activity. To
accomplish this, we treated our SY5Y-APP-Gal4 cells with
pharmacologic modulators of α-, β-, and γ-secretase activ-
ity and measured the effects using Western blot analyses
for APP cleavage products as well as AICD-Gal4 mediated
luciferase activity.
L-685,458 is a transition state inhibitor of γ-secretase that
prevents Aβ and AICD generation [35]. We treated SY5Y-
APP-Gal4 cells with L-685,458 (2.5 μM for 10 hours) or
with vehicle (DMSO) and collected cell lysates. We per-
formed Western blot analysis on these cell lysates using an
antibody to the C-terminus of human APP. In vehicle
treated cells we observe bands migrating at ~28 and ~26
kDa (Figure 2A). Cao and Sudhof observed a similar dou-
blet at approximately the same relative molecular weight.
They identified these bands as C83-Gal4 and AICD-Gal4,
respectively. In L-685,458 treated cells the intensity of the
C83-Gal4 band is significantly increased seven-fold (p <
0.01) and the AICD-Gal4 band is significantly decreased
by 80% (p < 0.01; Figure 2B). These results are consistent
with the substrate/product relationship between C83-
Gal4 and AICD-Gal4. The size difference between C83-
Gal4 and AICD-Gal4 is what is expected for γ-secretase
cleavage of C83-Gal4. It is also interesting to note that
AICD is normally difficult to detect by Western blot anal-
ysis, however the AICD-Gal4 fusion levels are quite high.
This suggests that AICD-Gal4 catabolism by IDE and/or
other proteases is greatly reduced compared to unmodi-
fied AICD [36].
L-685,458 treatment of SY5Y-APP-Gal4 cells results in a
concentration-dependent decrease in AICD-Gal4 medi-
ated luciferase activity; at a concentration of 2.5 μM there
is a ~75% decrease in luciferase activity (Figure 2C). The
L-685,458 concentration required for 50% inhibition of
AICD-Gal4 mediated luciferase activity is 1.25 μM.
The phorbol ester, PMA (phorbol 12-myristate 13-ace-
tate), stimulates α-secretase activity [37]. Treatment of
SY5Y-APP-Gal4 cells with PMA (1 μM for 10 hours)
resulted in approximately two-fold increase in the levels
of the α-secretase cleavage products sAPPα and C83-Gal4
(p < 0.01; Figures 3A &3B). In addition, Western blot anal-
ysis revealed a two-fold increase in AICD-Gal4 levels (p <
0.01; Figures 3A &3B). This two-fold increase in AICD-
Gal4 levels suggested that a similar PMA-induced increase
in AICD-Gal4 mediated luciferase activity should be
observed. Indeed, when we measured luciferase activity as
a function of increasing PMA concentration (Figure 3C),
we observed a dose-dependent increase in luciferase activ-
ity. The PMA-induced increases in luciferase activity pla-
teaus at 50 nM PMA. At concentrations of 50 nM andMolecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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higher, we observed approximately a two-fold increase in
AICD-Gal4 mediated luciferase activity in close agreement
with the observed two-fold increase in AICD-Gal4 by
Western blot analysis.
TAPI-1 (Tumor necrosis factor-α protease inhibitor 1)
inhibits α-secretase mediated shedding of the APP ectodo-
main [38]. Treating the SY5Y-APP-Gal4 cells with TAPI-1
(20 μM for two hours; Figure 3D &3E) resulted in a mod-
est, yet significant decrease of sAPPα (31%, p < 0.05),
C83-Gal4 (27%, p < 0.01) and AICD-Gal4 levels (36%; p
< 0.01), as well as in AICD-Gal4 mediated luciferase activ-
ity (38%; p < 0.01). In addition, TAPI-1 exhibits a dose-
dependent effect with 20 μM resulting in a 37% decrease
in AICD-Gal4 mediated luciferase activity (Figure 3F).
Again, these data show that alterations in AICD-Gal4 lev-
els as detected by Western blot can be accurately detected
by the AICD-Gal4 mediated luciferase assay.
Finally, we treated SY5Y-APP-Gal4 cells with a β-secretase
inhibitor (β-secretase inhibitor II). This inhibitor prevents
BACE-mediated cleavage of APP and generation of Aβ
[39]. Treating these cells resulted in no observable change
in AICD-mediated luciferase activity. This result is not sur-
prising given the very low levels of β-secretase cleaved APP
(C99-Gal4) that we observe in these cells compared to the
high levels of α-secretase cleaved APP (C83-Gal4) we
observe (Figures 2A, 3A, 3D). We estimate that of all the
APP molecules undergoing α- or β-secretase cleavage only
about 10% are cleaved by β-secretase, using our Western
blot data (data not shown). Therefore, inhibition of
BACE, even if effective, may result in an undetectable
change in the levels of cleavage products in this experi-
mental scheme.
In summary, pharmacologic modulation of α- and γ-
secretase activities alters AICD-Gal4 mediated luciferase
activities that accurately correspond to the changes in
AICD-Gal4 levels determined by Western blot analysis.
Genetic manipulation of secretase levels modulates AICD-
Gal4 mediated luciferase activity
To further validate the AICD-Gal4 mediated luciferase
assay as a reporter of APP metabolism, we over-expressed
and knocked-down the expression of genes involved in α-
, β- & γ-secretase activities. Again, we compared the effects
of over-expression or knock-down on levels of APP prote-
olytic products quantified by Western blot analysis to
AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4
cells.
Over-expression experiments were conducted by tran-
siently transfecting individual over-expression plasmids
or empty vector controls into the SY5Y-APP-Gal4 cells.
Cell lysates and conditioned media were collected 24 – 48
hours post transfection. ADAM10 and ADAM17 over-
expression promoted α-secretase cleavage of APP and
increased sAPPα secretion as compared to "empty vector"
transfected cells (Figure 4A – 4D). ADAM10 and ADAM17
over-expression also significantly increased C83-Gal4 and
Functional screen for regulators of APP metabolism Figure 1
Functional screen for regulators of APP metabolism. (A) Model depicting APP-Gal4 reporter system. (B) Firefly luci-
ferase activity is significantly increased in SH-SY5Y cells stably expressing APP-Gal4 and Gal4-UAS Luciferase compared to 
SY5Y cells stably expressing either Gal4/Gal4-UAS Luciferase or APP*-Gal4/Gal4-UAS Luciferase. Luciferase activity was nor-
malized to total cell number using SYBR Green. Bars represent mean normalized luciferase expression (+/- std. error) of 16 
independent trials for each cell line. Student's t-tests with sequential Bonferroni correction for multiple comparisons; ** indi-
cates p < 0.01.
  A                                                B   
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AICD-Gal4 levels as detected by Western blot (Figure 4A –
4D). Specifically, AICD-Gal4 levels increased approxi-
mately three-fold for both (Figure 4B &4D). Measuring
AICD-Gal4 mediated luciferase activity, we found that
over-expression of ADAM10 and ADAM17 resulted in a
statistically significant three to five fold increase in luci-
ferase activity (Figure 4E). Furthermore, over-expression
of the β-secretase gene (BACE) or individual components
of the γ-secretase complex (PSEN1,  PEN2,  APH1,  and
NCSTN) or another α-secretase member ADAM9 also
results in increased luciferase activity (Figure 4E). Specifi-
cally, BACE over-expression significantly increased luci-
ferase activity approximately two fold (p < 0.01), PEN2
and NCSTN over-expression increased luciferase activity
up to two fold (p < 0.01.) However, over-expression of
PSEN1 and APH1 did not result in any significant change
in luciferase activity.
We knocked-down the genes responsible for α- and γ-
secretase using commercially available shRNAs [40]. A
control shRNA, which is not complementary to any
known human gene, was used as a negative control. SY5Y-
APP-Gal4 cells were transfected with individual shRNAs
and selected with 2 μg/ml puromycin for 5 to 7 days. Con-
γ-secretase inhibition decreases AICD-Gal4 levels and AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 cells Figure 2
γ-secretase inhibition decreases AICD-Gal4 levels and AICD-Gal4 mediated luciferase activity in SY5Y-APP-
Gal4 cells. (A) Inhibition of γ-secretase by L-685,458 (5 mM) decreases AICD-Gal4 levels and increases C83-Gal4 levels as 
detected by Western blot analysis. (B) Quantification of Western blot densitometry in panel A. Normalization for loading dif-
ferences was achieved by dividing the densitometry values for individual bands by the densitometry values for β-actin in the 
same lane. (C) Dose-dependent decreases in AICD-Gal4-mediated luciferase activity with increasing concentrations of L-
685,458. For the luciferase experiments, points represent mean normalized luciferase activity (+/- standard error) of three 
independent trials, with luciferase levels normalized to total cell numbers using SYBR Green. Student's t-tests with sequential 
Bonferroni correction for multiple comparisons was utilized to test for significance. * indicates p < 0.05; ** indicates p < 0.01. 
"Control" uses the same media as the treatments, and also contains the same amount of DMSO.
A                                                                                                              B   
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Pharmacological modulation of α-secretase activity alters AICD-Gal4 levels and AICD-Gal4 mediated luciferase activity in  SY5Y-APP-Gal4 cells Figure 3
Pharmacological modulation of α-secretase activity alters AICD-Gal4 levels and AICD-Gal4 mediated luci-
ferase activity in SY5Y-APP-Gal4 cells. (A) Stimulation of α-secretase by PMA (1 μM PMA for 10 hours) increases sAPPα, 
C83-Gal4, and AICD-Gal4 levels as detected by Western blot analysis. (B) Quantification of Western blot densitometry in 
panel A. Normalization for loading differences was achieved by dividing the densitometry values for individual bands by the 
densitometry values for β-actin in the same lane. (C) Dose-dependent increases of AICD-Gal4-mediated luciferase activity with 
increasing concentrations of PMA (10 hour incubation). Luciferase levels normalized to total cell number using protein concen-
tration. (D) Inhibition of α-secretases by TAPI-1 (20 μM for two hours) results in decreases in sAPPα, C83-Gal4, and AICD-
Gal4 levels as detected by Western blot analysis. (E) Quantification of Western blot densitometry in panel D and normalized 
β-actin levels in the same lane. (F) Dose-dependent decreases in AICD-Gal4-mediated luciferase activity with increasing TAPI-
1concentrations (two hour incubation). For the luciferase experiments, points represent mean normalized luciferase activity 
(+/- standard error) of three independent trials, with luciferase levels normalized to total cell numbers using SYBR Green. Stu-
dent's t-tests with sequential Bonferroni correction for multiple comparisons; * indicates p < 0.05; ** indicates p < 0.01. "Con-
trol" uses the same media as the treatments and contains the same amount of DMSO as drug treated cells.
A                                                                                                   B 
              
                                                           C 
D                                                                                                     E 
            
                                                         F Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
Page 7 of 19
(page number not for citation purposes)
Over-expression of individual secretase genes in SY5Y-APP-Gal4 cells increases AICD-Gal4 mediated luciferase activity Figure 4
Over-expression of individual secretase genes in SY5Y-APP-Gal4 cells increases AICD-Gal4 mediated luci-
ferase activity. (A) Transient over-expression of ADAM10 increases ADAM10, AICD-Gal4, C83-Gal4, and sAPPα levels 
compared to cells transfected with empty vector. (B) Quantification of Western blot densitometry in panel A. (C) ADAM17 
transient over-expression significantly increases ADAM17, AICD-Gal4, C83-Gal4, and sAPPα levels. (D) Quantification of 
Western blot densitometry in panel C. (E) Transient over-expression of individual secretase genes increases AICD-Gal4 medi-
ated luciferase activity. Luciferase was normalized to transfection efficiency, by dividing by Renilla luciferase activity. Individual 
secretase over-expression plasmids were co-transfected with pRL-SV40 plasmid, expressing Renilla luciferase. Bars represent 
the mean normalized luciferase activity of four independent trials and error bars represent standard errors. Statistical signifi-
cance was determined using two-sample, one-tail t-tests to compare each secretase gene with the empty vector, followed by 
sequential Bonferroni procedure to adjust for multiple comparisons. * indicates p < 0.05; ** indicates p < 0.01.
A                                                           B  
       
C                                                           D  
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ditioned media and cell lysates were collected from these
cells and utilized for Western blot analyses and luciferase
assays. shRNAs specific for APP, ADAM10, and ADAM17
were tested for their ability to knock-down their target
genes (Figure 5A, 5B, 5C). Knock-down of these target
genes was robust and we have observed significant protein
knock-down with at least two different shRNA sequences
for each target gene. Consistent with this knock-down of
ADAM 10 and ADAM17, sAPPα levels were decreased sig-
nificantly (Figure 5D &5E). In addition, Western blot
analyses showed AICD-Gal4 levels were also decreased
when APP, ADAM10 and ADAM17 were knocked-down
(Figure 5E). Knock-down of these target genes also
decreased AICD-Gal4 mediated luciferase activity (Figure
5F). Specifically, APP knock-down significantly decreased
luciferase activity about 80% (p < 0.01); furthermore α-
secretase (ADAM10, and ADAM17) knock-down signifi-
cantly decreased luciferase activity 40–60% (p < 0.01).
Individual γ-secretase components, PSEN1, Pen2, APH1,
and NCSTN, were also knocked-down and this resulted in
significant 30–50% decreases in luciferase activity (p <
0.01).
Genetic manipulation of Fe65 and Tip60 levels modulates 
AICD-Gal4 mediated luciferase activity
To determine if changes in AICD metabolism modulated
AICD-Gal4 mediated luciferase activity, we over-
expressed and knocked-down Fe65 and Tip60. Transient
over-expression of Fe65 significantly increased luciferase
activity more than two-fold (p < 0.01), while transient
over-expression of Tip60 resulted in a 30% increase in
luciferase activity that was not significant (Figure 6A).
Knock-down of Fe65 and Tip60 resulted in a significant
40–50% decrease in luciferase activity (Figure 6B; p <
0.01).
Ubiquilin 1 regulates AICD-Gal4 levels
Having shown that monitoring AICD-Gal4 mediated luci-
ferase activity accurately measures changes in AICD-Gal4
levels induced by changes in secretase activity/levels, we
wanted to determine if this approach could detect regula-
tors with a less direct role in APP proteolysis and AICD
signaling. We decided to test Ubiquilin 1 because (i) the
gene encoding Ubiquilin 1 (UBQLN1) is located in a
region of chromosome 9 that displays linkage to AD in
several independent samples [41-46], (ii) a polymor-
phism in UBQLN1  modulates AD risk in several inde-
pendent samples [47-49], (iii) Ubiquilin 1 can modulate
APP trafficking to the cell surface in HEK-293 and H4 cell
lines [31], and (iv) Ubiquilin 1 can modulate γ-secretase
activity, though the consequences of this modulation on
γ-secretase substrates were not determined [32-34]. Given
this, testing Ubiquilin 1 would determine if our genetic
screen can detect regulators of APP trafficking and prese-
nilin endoproteolysis. Furthermore, the role of Ubiquilin
1 in APP metabolism regulation has not been previously
investigated in SH-SY5Y cells.
SY5Y-APP-Gal4 cells were transfected separately with five
different Ubiquilin 1 shRNAs, APP shRNA and the control
shRNA. Cell lysates were collected and utilized for luci-
ferase assays. Individually, all five Ubiquilin 1 shRNA
constructs significantly decreased luciferase activity. They
resulted in 50% (p < 0.01), 60% (p < 0.01), 40% (p <
0.01), 60% (p < 0.01), and 60% (p < 0.01) decreases in
luciferase activity, respectively (Figure 7A) as compared to
cells expressing the control shRNA. To confirm the role of
Ubiquilin 1 in AICD-mediated transcriptional activity
suggested by these results, we transiently over-expressed
Ubiquilin 1 in SY5Y-APP-Gal4 cells and measured luci-
ferase activity. We observed that Ubiquilin 1 over-expres-
sion resulted in an approximately 90% (p < 0.05) increase
in luciferase activity compared to the empty vector control
(Figure 8A).
Ubiquilin 1 regulates APP and PS1
To begin to gain insight into the mechanism(s) by which
Ubiquilin 1 modulates AICD-Gal4 mediated luciferase
expression, we utilized Western blot analysis of cell lysates
and conditioned media from SY5Y-APP-Gal4 cells in
which Ubiquilin 1 was knocked-down or over-expressed
to monitor APP and Ubiquilin 1 metabolism. Specifically,
we analyzed cell lysates and conditioned media of cells
expressing Ubiquilin 1 shRNA number 2, since transfec-
tion with this shRNA led to the largest decrease in luci-
ferase activity. Expression of this shRNA resulted in a
robust Ubiquilin 1 knock-down and led to significantly
decreased levels of mature full-length APP, immature full-
length APP, AICD-Gal4, C83-Gal4, and sAPPα (Figures 7B
&7C). To determine if Ubiquilin 1-induced changes in
APP mRNA levels underlie the observed changes in full
length APP levels, we performed real-time, quantitative
PCR on SY5Y-APP-Gal4 cells stably expressing either con-
trol or Ubiquilin 1 shRNAs. No Ubiquilin 1-induced
changes in APP mRNA levels were observed (Figures 7D).
This suggests that Ubiquilin 1 regulation of full-length
APP levels occurs post-transcriptionally.
We studied Ubiquilin 1 over-expression to determine if
we observed the converse effects on APP proteolytic prod-
ucts and full-length APP. Indeed, we observed that Ubiq-
uilin 1 over-expression resulted in increased levels of
mature and immature full-length APP, AICD-Gal4, C83-
Gal4, and sAPPα (Figures 8B &8C).
The Ubiquilin 1-induced effects on full-length APP are
greater on mature APP levels than on immature APP levels
(Figure 7C &8C). This results in a decrease in the ratio of
mature to immature full-length APP-Gal4 when Ubiquilin
1 is knocked-down (p < 0.01; Figure 7C) and an increaseMolecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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Knock-down of APP and individual secretase genes in SY5Y-APP-GAL4 cells decreases AICD-Gal4 mediated luciferase activity Figure 5
Knock-down of APP and individual secretase genes in SY5Y-APP-GAL4 cells decreases AICD-Gal4 mediated 
luciferase activity. (A) APP-specific shRNA decreases full-length APP, C83-Gal4, and AICD-Gal4 levels compared to the 
control or "non-silencing" shRNA. Results from duplicate transfections with each shRNA are shown. (B) ADAM10 specific 
shRNAs decrease endogenous ADAM10, C83-Gal4, and AICD-Gal4 levels compared to the control shRNA. Results from 
duplicate transfections with each shRNA are shown. (C) ADAM17 specific shRNAs decrease endogenous ADAM17, C83-Gal4, 
and AICD-Gal4 levels compared to the control shRNA. Results from duplicate transfections with each shRNA are shown. (D) 
Knock-down of ADAM9, 10, and 17 decrease sAPPα levels compared to control shRNA. (E) Quantification of Western blot 
densitometries in panels B – D. (F) Transfection with shRNAs specific for APP and individual secretase genes decreases AICD-
Gal4-mediated luciferase expression compared to control shRNA. Bars represent the mean normalized luciferase activity of 
four independent trials and error bars represent standard errors. Statistical significance was determined using two-sample, one 
tailed t-tests to compare each secretase shRNA with the control shRNA and sequential Bonferroni procedure to adjust for 
multiple comparisons. * indicates p < 0.05; ** indicates p < 0.01.
A                                                            B                                         
       
C                                                            D                                         
       
E                                                            F     
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in this ratio when Ubiquilin 1 is over-expressed (p < 0.05;
Figure 8C).
Since Ubiquilin 1 has been reported to regulate PS1 endo-
proteolysis in HEK-293 cell lines, we sought to determine
if the Ubiquilin 1-induced changes that we observed in
AICD-Gal4 and C83-Gal4 levels may be due in part to
changes in PS1 endoproteolysis [34]. Ubiquilin 1 knock-
down in SY5Y-APP-Gal4 cells decreased PS1 carboxy-ter-
minal fragment levels (PS1-CTF; Figure 9A) and Ubiquilin
1 over-expression increased PS1-CTF levels (Figure 9B).
We did not observe any changes in the levels of ADAM 10,
ADAM 17 or BACE when Ubiquilin 1 was over-expressed
or knocked-down (data not shown).
Finally, we over-expressed Ubiquilin 1 in naïve SH-SY5Y
to ensure that the results we observed are not limited to
the SY5Y-APP-Gal4 cell line. We found that in these naïve
cells Ubiquilin 1 over-expression resulted in increased
total, mature and immature APP, sAPP as well as PS1 CTF,
consistent with our findings in SY5Y-APP-Gal4 cells (data
not shown).
Discussion
Taking advantage of the APP intracellular domain's
(AICD) ability to activate transcription, we established an
assay to monitor APP metabolism in the human neurob-
lastoma cell line, SH-SY5Y. We are using this assay in
combination with RNAi-mediated knock-down of posi-
tional candidate genes as a genetic screen to identify regu-
lators of APP metabolism. Here we describe validation of
this experimental approach using pharmacologic and
genetic modulation of known APP metabolism regula-
tors. We find that AICD-Gal4 mediated luciferase activity
is significantly and accurately changed when secretases,
Fe65, Tip60, or Ubiquilin 1 levels/activities are modu-
lated pharmacologically or genetically. The ability of
Ubiquilin 1 to regulate APP metabolism in SH-SY5Y cells
had not been investigated previously. Our initial findings
show that in these cells Ubiquilin 1 regulates total APP
levels, APP maturation and PS1 endoproteolysis. Our
results lead us to conclude that the genetic screen we
describe is capable of identifying genes that encode regu-
lators of APP proteolysis, APP maturation, APP levels, and
AICD activity.
Validation of AICD-Gal4 luciferase assay
The functional assay for identifying APP metabolism reg-
ulators relies on the ability of an AICD-Gal4 fusion to
transactivate a firefly luciferase reporter gene [16]. While
the biological role of AICD-mediated transactivation is
unclear [20,23,24,50], we utilized this transactivation
function purely as a reporter of APP processing and there-
fore APP metabolism. We determined that monitoring
AICD-Gal4 mediated luciferase activity is correlated to
AICD-Gal4 levels by utilizing pharmacologic and genetic
agents to regulate secretase activities and thereby modu-
late AICD-Gal4 levels. In SH-SY5Y cells stably expressing
an APP-Gal4 fusion protein and a Gal4-UAS driven luci-
ferase reporter construct (SY5Y-APP-Gal4 cells), we uti-
Genetic alteration of Fe65 or Tip60 levels modulates AICD-Gal4 mediated luciferase activity Figure 6
Genetic alteration of Fe65 or Tip60 levels modulates AICD-Gal4 mediated luciferase activity. (A) Transient over-
expression of Tip60 or Fe65 in SY5Y-APP-Gal4 cells increases AICD-Gal4 production compared to empty vector controls. (B) 
Knock-down of Fe65 or Tip60 in SY5Y-APP-Gal4 cells decreases AICD-Gal4 mediated luciferase activity Bars represent the 
mean normalized luciferase activity of four independent trials and error bars represent standard errors. Statistical significance 
was determined using two-sample, one-tailed t-tests to compare each secretase gene and "vector" or "control" and sequential 
Bonferroni procedure to adjust for multiple comparisons. * indicates p < 0.05.Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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lized TAPI-1 and L-685,458 to inhibit α- and γ-secretases
respectively. TAPI-1 inhibits α-secretase cleavage of APP as
well as several other cell surface proteins including TNFα
[38]. L-685,458 is a potent and selective cell-permeable γ-
secretase inhibitor [51]. Both of these inhibitors decreased
AICD-Gal4 levels and decreased AICD-Gal4 mediated
luciferase activity to similar levels. Inhibiting BACE activ-
ity did not have an appreciable effect on AICD-Gal4 levels
or AICD-Gal4 mediated luciferase activity, which is not
surprising since the majority of APP processing occurs via
the α-secretase pathway in SH-SY5Y cells. Stimulation of
α-secretase using PMA [52] increased AICD-Gal4 levels
and increased AICD-Gal4 mediated luciferase activity to
similar levels.
To further validate our functional assay, we over-
expressed and knocked-down genes that encode the α-, β-
, and γ-secretases. Similar to the effects of pharmacologic
Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in SY5Y-APP-Gal4 cells Figure 7
Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in SY5Y-APP-Gal4 cells. (A) Ubiquilin 1 knock-down 
decreases AICD-Gal4-mediated luciferase activity. SY5Y-APP-Gal4 cells stably expressing the control shRNA, an APP specific 
shRNA, or five different shRNA targeting Ubiquilin 1 were generated. Cell lysates were utilized to measure AICD-Gal4 medi-
ated luciferase activity. Bars represent the mean normalized luciferase activity (+/- standard error) of six independent trials. (B) 
SY5Y-APP-Gal4 cells stably expressing Ubiquilin 1 specific shRNA (#2) have decreased Ubiquilin 1, mature and immature APP-
Gal4, C83-Gal4, AICD-Gal4, and sAPPα levels compared to cells expressing control shRNA. (C) Quantification of Western 
blot results. Bars represent mean densitometry (+/- standard error) of three independent trials. Black bars represent the den-
sitometry from Ubiquilin 1 knock-down cells; white bars represent the densitometry from cells expressing control shRNA. 
Abbreviations: Ma APP denotes mature APP, Im APP denotes immature APP; Ma/Im APP denotes the mature APP/immature 
APP ratio. Statistical significance between mock and over-expression for each measure was determined using a two-sample, 
one tailed t-test and sequential Bonferroni procedure to adjust for multiple comparisons. * indicates p < 0.05; ** indicates p < 
0.01. (D) Ubiquilin 1 knock-down does not alter APP mRNA levels compared to control shRNA as measured by quantitative 
PCR.
                                                                                            B                                                       
                    
  C                                                                                         D                      
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modulators of secretases, over-expressing or knocking-
down secretase genes resulted in predictable alterations in
AICD-Gal4 levels as measured by Western blot analysis.
The changes in luciferase activity induced by secretase
over-expression or knock-down mirrored the trends
observed in the Western blot analysis. Knock-down of
APP had the most dramatic effect on AICD-Gal4 mediated
luciferase activity while knock-down of genes encoding α-
and γ-secretases resulted in significant decreases in AICD-
Gal4 mediated luciferase.
To assess the quality of the AICD-Gal4 mediated luciferase
assay we calculated the "Z-factor" for the assay in response
Ubiquilin 1 over-expression regulates APP-Gal4 metabolism  in SY5Y-APP-Gal4 cells Figure 8
Ubiquilin 1 over-expression regulates APP-Gal4 
metabolism in SY5Y-APP-Gal4 cells. (A) Transient 
Ubiquilin 1 over-expression increases AICD-Gal4 mediated 
luciferase activity. SY5Y-APP-GAL4 cells were transiently co-
transfected with UBQLN1 over-expression plasmid and a 
Renilla luciferase over-expression plasmid (pRL-SV40). The 
latter was used as a transfection efficiency control to normal-
ize AICD-Gal4 mediated luciferase activity. Bars represent 
the mean normalized luciferase activity (+/- standard error) 
of six independent trials. Statistical significance was deter-
mined using two-sample, one-tailed t-tests to compare each 
experimental shRNA to the control shRNA and sequential 
Bonferroni procedure to adjust for multiple comparisons. (B) 
SY5Y-APP-Gal4 cells transiently over-expressing Ubiquilin 1 
have increased Ubiquilin 1, mature and immature APP-Gal4, 
C83-Gal4, AICD-Gal4, and sAPPα levels compared to vector 
only cells. (C) Quantification of Western blot results. Bars 
represent mean densitometry (+/- standard error) of three 
independent trials. Black bars represent the densitometry 
from Ubiquilin 1 over-expressing cells; white bars represent 
the densitometry from cells expressing empty vector con-
trol. Abbreviations: Ma APP denotes mature APP, Im APP 
denotes immature APP; Ma/Im APP denotes the mature APP/
immature APP ratio. Statistical significance between mock 
and over-expression for each measure was determined using 
a two-sample, one tailed t-test and sequential Bonferroni 
procedure to adjust for multiple comparisons. * indicates p < 
0.05; ** indicates p < 0.01.
              A                                                         
                B                                 
    C  
Ubiquilin 1 regulates Presenilin 1 endoproteolysis in SY5Y- APP-Gal4 cells Figure 9
Ubiquilin 1 regulates Presenilin 1 endoproteolysis in 
SY5Y-APP-Gal4 cells.(A) Ubiquilin 1 knock-down 
decreases PS1 CTF levels in SY5Y-APP-Gal4 cells. (B) Ubiqui-
lin 1 over-expression increases PS1 CTF levels in SY5Y-APP-
Gal4 cells.
A
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to the known APP metabolism modulators[53]. The Z-fac-
tor is a dimensionless metric that takes assay dynamic
range and data variation into consideration to assess the
utility and reliability of the assay. Scores between 0.5 and
1.0 indicate an excellent assay [53]. Using the data we col-
lected, we calculated Z-factors for pharmacologic and
genetic modulation of the secretases (Table 1). For all of
these conditions we obtain Z values between 0.5 and 1.0,
indicating that our experimental approach is robust and
has the capability of identifying APP metabolism regula-
tors that increase or decrease AICD generation.
AICD metabolism regulators modulate AICD-Gal4 
luciferase activity
AICD-Gal4 mediated transactivation has been shown to
require Fe65 and Tip60. Fe65 is an adaptor protein that
binds to the NPTY sequence in AICD and mediates intra-
cellular trafficking of AICD-Gal4 from the cytoplasm into
the nucleus [16]. Once inside the nucleus, the AICD-Gal4/
Fe65 complex recruits the histone acetyltransferase,
Tip60. Fe65 and Tip60 are both required for AICD-Gal4
transactivation activity. We observed increased AICD-
Gal4 mediated luciferase activity when we over-expressed
Fe65 or Tip60 and decreased luciferase activity when
either of these genes was knocked-down.
Ubiquilin 1 modulates APP metabolism in SH-SY5Y cells
Having validated our experimental approach using direct
regulators of APP proteolysis and AICD-metabolism, we
then sought to determine if Ubiquilin 1 could modulate
AICD-Gal4 mediated luciferase activity. Ubiquilin 1 has
been shown to regulate presenilin1 endoproteolysis and
APP trafficking in HEK-293 cells [31-34] and therefore
testing Ubiquilin 1 would help to determine whether our
experimental approach could detect APP metabolism reg-
ulators that are not directly involved in APP proteolysis
nor in AICD signaling. When Ubiquilin 1 was knocked-
down, AICD-Gal4 luciferase activity was significantly
decreased.
Ubiquilin 1 is a conserved protein that contains an NH2-
terminal ubiquitin-like domain (UBL) and a COOH-ter-
minal ubiquitin-associated (UBA) domain [32]. Through
these domains, Ubiquilin 1 associates with ubiquitin
ligases and the proteosome and is proposed to link ubiq-
uitination with proteosome-mediated protein degrada-
tion. This suggests that Ubiquilin 1 plays a role in
responding to protein misfolding, aggregation, and/or
stress [32,54]. In the brains of AD patients, there is
increased Ubiquilin 1 in neurons containing neurofibril-
lary tangles (NFTs), as compared to control brains [32]. In
the brains of Parkinson's disease patients, as well as
patients with diffuse Lewy body disease (DLBD), there is
strong Ubiquilin 1 staining of Lewy bodies [32]. Finally, a
polymorphism in the UBQLN1 gene has been shown to
increase AD risk in family-based and large case-control
samples [47-49].
The role of Ubiquilin 1 in AD pathogenesis may be due to
its ability to regulate formation of active γ-secretase com-
plexes and/or regulate APP trafficking [31-34]. Monteiro
and colleagues have found that Ubiquilin 1 can regulate
full-length Presenilin1 (PS1), Presenilin2 (PS2), Nicas-
trin, and PEN-2 levels as well as PS1 and PS2 endoprote-
olysis [32-34]. Specifically, Ubiquilin 1 over-expression
increased full-length presenilin (PS1 and PS2) levels in
HeLa cells. In HEK-293 cells, Ubiquilin 1 over-expression
decreased presenilin endoproteolysis while Ubiquilin 1
knock-down increased presenilin endoproteolysis [34]. In
addition, Monteiro and colleagues show that nicastrin
and Pen-2 levels are decreased by Ubiquilin 1 over-expres-
sion and increased by Ubiquilin 1 knock-down in HEK-
293. In addition to these effects on γ-secretase compo-
nents, Hiltunen and colleagues reported that Ubiquilin 1
knock-down decreased steady-state full-length immature
APP levels, increased trafficking of APP from intracellular
compartments to the cell surface, and increased steady-
state sAPPα levels in HEK-293 and H4 cell lines [31].
These effects on APP levels and secretion altered Aβ40 and
Aβ42 levels. However, Ubiquilin 1 knock-down did not
alter α-, β-, or γ-secretase levels or C83 and C99 levels in
these cell lines.
Here we found that in the human neuroblastoma cell line,
SH-SY5Y, Ubiquilin 1 regulates total full-length APP, the
ratio of mature to immature APP, as well as PS1 endopro-
teolysis. To arrive at these conclusions, we over-expressed
and knocked-down Ubiquilin 1 in SY5Y-APP-Gal4 cells
and monitored APP metabolism using Western blot anal-
ysis. We found that Ubiquilin 1 knock-down decreased
levels of AICD-Gal4, C83-Gal4, sAPPα, full-length mature
and immature APP, and the ratio of mature to immature
APP. Ubiquilin 1 over-expression elicited the opposite
effect on the levels of these molecules.
Table 1: Z-factor values
APP Metabolism Modulators Z factor
Pharmacological PMA 0.77
TAPI-1 0.63
L685,458 0.74
shRNA APP 0.60
ADAM10 0.71
ADAM17 0.70
Over-expression ADAM10 0.72
ADAM17 0.60
Z-factor values for AICD-Gal4 Luciferase assay calculated when APP 
metabolism is modulated by pharmacologic or genetic approaches.Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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The fact the ratio of mature to immature APP is altered by
Ubiquilin 1 in the absence of APP mRNA level changes
suggests that Ubiquilin 1 modulates trafficking through
the secretory pathway in SH-SY5Y cells. This conclusion
was reach by Hiltunen and colleagues when investigating
the role of Ubiquilin 1 on APP metabolism in H4 and
HEK-293 cell lines [31].
Given the existing reports that Ubiquilin 1 regulates PS1
levels and endoproteolysis in HeLa and HEK-293 cells,
respectively, we sought to determine if the observed
changes in APP processing may be due, in part, to Ubiqui-
lin 1 mediated changes in PS1 metabolism [32-34]. Inter-
estingly, Hiltunen and colleagues did not observe any
changes in PS1 levels or endoproteolysis upon transient
Ubiquilin 1 knock-down in HEK-293 [31]. In SY5Y-APP-
Gal4 cells, we observed that Ubiquilin 1 knock-down
decreases PS1 endoproteolysis and Ubiquilin 1 over-
expression promotes PS1 endoproteolysis. Presumably
these changes in PS1-CTF levels alter γ-secretase activity
and cleavage of other γ-secretase substrates. At this time, it
is not clear how Ubiquilin 1 regulates PS1 endoproteoly-
sis. No alterations in ADAM10, ADAM17, or BACE levels
were observed when Ubiquilin 1 was knocked-down or
over-expressed. These results suggest that Ubiquilin 1 reg-
ulates APP metabolism not only by controlling the ratio
of mature to immature APP but also by post-transcription-
ally controlling total APP (mature and immature) levels
and PS1 endoproteolysis.
It is interesting to note that the effects of Ubiquilin 1 over-
expression/knock-down on APP and presenilin metabo-
lism that we observe in SH-SY5Y cells are different than
those observed in HEK-293 and HeLa cells [31,34]. In SH-
SY5Y cells we find Ubiquilin 1 knock-down decreased
total, mature, and immature full-length APP, sAPPα, C83
and AICD steady-state levels and the ratio of mature to
immature APP, while over-expression increased these
same steady-state levels. In addition, Ubiquilin 1 over-
expression increased PS1 endoproteolysis. In HEK-293
cells, Hiltunen et al. found that Ubiquilin 1 knock-down
decreased steady-state immature full-length APP levels,
increased sAPPα levels, and no effects were observed in
C83, C99, AICD, and PS1 CTF levels [31]. However, Mas-
sey et al. observed an increase in PS1 endoproteolysis in
HEK-293 cells [34]. In SH-SY5Y cells however, Ubiquilin
1 seemingly has opposite effects on APP and presenilin
metabolism than observed in HEK-293. At this time the
reasons for these differences are not clear; they could be
due to differences in experimental procedure (e.g. differ-
ences in cell confluency, and/or RNAi techniques [tran-
sient siRNA versus stable shRNA]) and/or inherent
differences in these two cell types. One of the noticeable
differences between these cells is that in SH-SY5Y cells, the
majority of full-length APP is mature, whereas in HEK-
293 the majority of full-length APP is immature (data not
shown). Cell type dependent effects of Ubiquilin 1 have
been observed previously. In COS7 cells, Ubiquilin 1
over-expression reduced cell surface expression of nico-
tinic acetylcholine receptors (nAChRs), while in superior
cervical ganglion neurons Ubiquilin 1 over-expression
had no effect on nAChR levels [55]. These cell type-
dependent effects are interesting given the differential vul-
nerability observed in AD brains, where subsets of neocor-
tical and hippocampal neurons preferentially degenerate
[56]. In addition to these cell type-dependent effects,
Ubiquilin 1 has been shown to function in seemingly
opposite ways. Ubiquilin 1 over-expression has been
shown to promote accumulation of some proteins
[HASH-1[57], HES-1[57], and GABAA  receptor[58]] as
well as to promote degradation of other proteins
[nAChRs[55] and Hepatitis C virus RNA-dependent RNA
polymerase [NS5B][59]]. It will be important to study the
role of Ubiquilin 1 on APP metabolism in primary neu-
rons and in vivo to determine its true role in regulating
APP metabolism and in AD pathogenesis.
Our Ubiquilin 1 results suggest that in SH-SY5Y cells,
Ubiquilin 1 regulates APP metabolism not only by con-
trolling the ratio of mature to immature APP but also by
post-transcriptionally controlling total APP (mature and
immature) levels and PS1-CTF levels.
AICD-Gal4 luciferase assay accurately reports AICD-Gal4 
levels
Finally, we were struck by the ability of the AICD-Gal4
mediated luciferase assay to accurately report AICD-Gal4
levels. To determine if these measures of AICD-Gal4 were
correlation, we plotted the change in luciferase activity
versus the change in AICD-Gal4 levels as measured by
Western blot analysis. AICD-Gal4 levels were modulated
by pharmacologic or genetic modulation of secretases and
Ubiquilin 1. This analysis revealed a strong and significant
correlation between AICD-Gal4 levels and AICD-Gal4-
mediated luciferase expression (Figure 10; R2 = 0.95; p = 6
*10-6). The best fit line of this relationship has a slope
close of 0.71 demonstrating that this luciferase assay pro-
vides an accurate reporter of changes in AICD-Gal4 levels.
In addition, measuring AICD-Gal4 mediated luciferase
activity provides a simple, quick and inexpensive means
for monitoring changes in APP metabolism. The genetic
screen we describe can be successfully utilized to identify
genes that putatively modulate AICD-Gal4 levels. Addi-
tional assays, including as Western blot and ELISA, will be
necessary to confirm their role in APP metabolism regula-
tion and gain insight into the mechanism of regulation.
Conclusion
We have established and validated an AICD-Gal4 based
functional assay in SH-SY5Y cells. Using this assay in com-Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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bination with RNAi, we have developed a genetic screen
to identify regulators of APP metabolism. This screen
accurately, robustly, and easily measures changes in
AICD-Gal4 levels. We demonstrate that these AICD-Gal4
levels can be altered by pharmacologic or genetic modula-
tion of genes that directly regulate APP levels, AICD traf-
ficking/signaling, APP maturation, and APP proteolysis.
Using this approach, we show that Ubiquilin 1 can regu-
late AICD-Gal4 levels in SH-SY5Y cells. Ubiquilin 1 regu-
lates AICD-Gal4 levels by modulating APP levels, the ratio
of mature to immature APP, and PS1 endoproteolysis.
Taken together, our results demonstrate that this genetic
screen is capable of identifying APP metabolism regula-
tors that can modulate the APP proteolytic processing,
APP maturation, APP levels, and AICD trafficking/signal-
ing.
Methods
Chemicals and antibodies
Phorbol 12-myristate 13-acetate (PMA), L-685,458, and
puromycin were purchased from Sigma. TAPI-1 was pur-
chased from Peptides International. β-secretase inhibitor
II, N-Benzyloxycarbonyl-Val-Leu-leucinal Z-VLL-CHO,
was purchased from Calbiochem. The APP C-terminal
antibody (A8717; 1:1000) and β-actin antibody
(1:10,000) were purchased from Sigma. The 6E10, anti-
APP antibody was purchased from Covance and utilized
for detection of sAPPα (1:1000). The BACE1 antibody
(1:1000) was purchased from Bioscience. The ADAM10
(C-terminal) antibody (1:1000) was purchased from Pro-
Sci. The Ubiquilin 1 antibody (1:160) was purchased
from Zymed. The ADAM17 antibody (1:1000) was pur-
chased from Chemicon. The HRP-conjugated secondary
antibodies (anti-mouse and anti-rabbit) (1:10,000) were
purchased from GE.
Plasmids
The plasmids APP-Gal4, APP*-Gal4 and Gal4, Gal4-UAS-
luciferase (encoding firefly luciferase) were kindly pro-
vided from Dr. Thomas Südof, and are described else-
where [16]. Briefly, each of these plasmids encodes only
the DNA binding domain of Gal4. The ADAM10 over-
expression plasmid was kindly provided by Dr. Paul
Saftig. The ADAM9 and ADAM17 were provided by Dr.
Carl Blobel. The empty vector of ADAM9, ADAM10 and
ADAM17 is pcDNA3.1. Ubiquilin 1 over-expression plas-
mid, which was constructed from pCMV vector, was
kindly provided by Dr. Mervyn J. Monteiro.
Cells and cell culture
SH-SY5Y and naïve human embryonic kidney (HEK)-293
cells were purchased from ATCC. These cell lines were cul-
tured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 units/ml penicillin, and 100 μg/ml strep-
tomycin. SH-SY5Y cells that stably express APP-Gal4,
APP*-Gal4, or Gal-4, and carrying the Gal4-UAS-luci-
ferase reporter construct were constructed by co-transfect-
ing one of the Gal4 constructs, the pCDNA3.1 plasmids,
along with the Gal4-UAS plasmid, and selecting resistant
clones with 400 μg/ml G418. These cells were then tested
for γ-secretase dependent luciferase activity. Clonal lines
that stably express luciferase were obtained and were
maintained with media containing 200 μl/ml G418.
RNAi
Plasmid-based shRNA constructs were purchased from
Open-Biosystems (Birmingham, AL). These constructs are
part of the human retroviral shRNA library housed at the
Drexel University RNAi Resource Center. We utilized the
following target specific shRNAs: for UBQLN1 shRNAs
(Open Biosystems catalog #s: v2HS_58534,
v2HS_254856, v2HS_254715, v2HS_255129 and
v2HS_58531); for ADAM9 shRNAs (V2HS_17130,
V2HS_17127, V2HS_17126, and V2HS_17129); for
ADAM10 shRNAs (v2HS_94294, v2HS_94297, and
v2HS_94295); for ADAM17 shRNAs (RHS3979-9619367,
RHS3979-9619368, RHS3979-9619369, and RHS3979-
9619370); for BACE1 shRNAs (V2HS_25207,
V2HS_25209, V2HS_25206, V2HS_25205, V2HS_25210);
for PSEN1 shRNAs (v2HS_89932, v2HS_89931); for
PSEN2 shRNAs (v2HS_93093); for APH1 shR-
NAs(v2HS_117094, v2HS_117096); for NCSTN shR-
Correlation between AICD-Gal4 mediated luciferase levels  and AICD-Gal4 levels determined by Western blot analysis Figure 10
Correlation between AICD-Gal4 mediated luciferase 
levels and AICD-Gal4 levels determined by Western 
blot analysis. Using data from pharmacologic (PMA, TAPI-1, 
L-685,458), over-expression (ADAM 10, ADAM17, Ubiquilin 
1) or knock-down (ADAM 10, ADAM17, Ubiquilin 1) medi-
ated modulation of AICD-Gal4 levels we plotted the average 
fold change in AICD-Gal4 levels versus the average fold 
change in AICD-Gal4 mediated luciferase activity. For tran-
sient over-expression, luciferase activity and AICD-Gal4 lev-
els were normalized to transfection efficiency by Renilla 
luciferase activity assays. The line is represents the least 
squares linear regression to this data.Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
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NAs(v2HS_255892). As a negative control shRNA, we
utilized the non-silencing shRNA from Open Biosystems,
Inc. (RHS 1707). shRNA constructs were transfected using
Arrest-In transfection reagent (Open Biosystems, Inc.)
using the conditions suggested by the manufacturer. Stably
expressing shRNA clones were generated by adding 2 μg/
ml puromycin 24 hours post-transfection. Populations of
resistant clones were detected five to seven days post-trans-
fection.
Western Blot Analysis
Cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCL
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM
PMSF and 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1
μg/ml pepstatin), and centrifuged at 14,000 rpm for 15
minutes at 4°C. The resulting supernatant was transferred
to a new micro-centrifuge tube. The protein concentration
of the cell lysates was determined using the BCA protein
assay kit (Pierce, Rockford, IL) according to the manufac-
turer's instructions. Equal quantities of protein were
loaded into the wells of 4–12% Bis-Tris polyacrylamide
gels (Invitrogen) along with See Blue plus 2 protein
marker (Invitrogen). Gels were run using MES running
buffer and transferred to PVDF membrane (Immobilon
PSQ, Millipore) using a semi-dry transfer apparatus (Owl
Scientific) and NuPage transfer buffer (Invitrogen). PVDF
membranes were blocked in TBST with 5% dry milk for at
least two hours, washed extensively, then incubated with
primary antibody for either one hour at room temperature
or overnight at 4°C. After removing the primary antibody,
membranes were extensively washed and incubated with
either goat-anti-rabbit-HRP or goat-anti-mouse-HRP sec-
ondary antibodies (1:10,000; GE) for one hour at room
temperature. Membranes were washed and developed
using West Dura Extended Duration Substrate (Pierce).
The blot was visualized using a FluoroChem 8900 imag-
ing system (Alpha Innotech), and signals were quantified
using AlphaEase Fc software. To account for any differ-
ences in loading, target band densitometries were divided
by actin densitometries obtained from the same lane.
These corrected densitometries were normalized to con-
trols in each experiment.
Detection of sAPPα followed the protocol detailed in
Lanni et al. and Bergamaschi et al. [52,60]. Briefly, condi-
tioned media was collected and 48% trichloroacetic acid
(TCA) was added so that the TCA final concentration was
15%. This mixture was incubated on ice for 30 minutes,
and centrifuged at 14,000 rpm for 20 minutes. Following
this spin, the supernatant was aspirated and discarded.
500 μl of ice cold acetone was used to resuspend the pel-
let. This mixture was placed at -20°C for at least 30 min-
utes, followed by centrifugation at 14,000 rpm for 20
minutes. The supernatant was carefully aspirated and dis-
carded. The remaining pellet was air dried for 10 minutes
and then 20 μl of RIPA was added and this sample was uti-
lized for Western blot analysis. The sAPPα bands were
detected using the 6E10 (1:1000) as the primary antibody.
Luciferase assays
For firefly luciferase assays, 7,500 cells were plated into
the 96 well plates. In an experiment, each treatment was
applied to a total of six wells. After treatments, condi-
tioned media was aspirated and discarded. 100 μl GLB
(Glo Lysis Buffer, Promega) was added to lyse the cells. 30
μl of each cell lysates was transferred to a white plate
(Greiner Bio-one), and 30 μl Steady-Glo (Promega) was
added. Luciferase was measured using a Top-Count Scin-
tillation Counter/Luminescence Reader (Packard, Inc.)
Another 30 ul of each cell lysates was transferred to the
other white color plate, and 30 μl 20× SYBR Green
(diluted in PBS from Invitrogen 10,000× SYBR Green) was
added. SYBR Green fluorescence was measured after 5
minutes incubation in dark using an excitation wave-
length of 485 nm, and emission wavelength of 527 nm,
and an integration time of 0.1 seconds on a Fluoroscan
Ascent FL fluorescence plate reader (Thermo Labsystems,
Inc.). The luciferase signal was normalized to cell number
by dividing the luciferase signal by the SYBR Green read-
ing for the same well. For dual luciferase assays, SH-SY5Y-
APP-Gal4 cells that stably express firefly luciferase were
co-transfected with pRL-SV40, which constitutively over-
expresses  Renilla  luciferase, along with other plasmids.
The dual luciferase assay was performed 24 – 48 hours
post-transfection. The media was aspirated and discarded.
30 μl Dual-Glo luciferase substrate (Promega) was added
to lyse the cells. All cell lysates were resuspended and
transferred to a white 96 well plate (Greiner Bio-one).
After 10 minutes incubation at room temperature, firefly
luciferase was measured using a Top-Count Scintillation
Counter/Luminescence Reader (Packard, Inc.). Next, 30 μl
Stop-Glo substrate (Promega) was added to the cell
lysates containing Dual-Glo. After 10 minutes room tem-
perature incubation, Renilla  luciferase was measured
using the same Top-Count Scintillation Counter/Lumi-
nescence Reader (Packard, Inc.) For normalization, the
firefly luciferase signal was divided by the Renilla  luci-
ferase signal for the same well. In an experiment, each
treatment was applied to a total of four wells.
RNA Extraction and Real-time, Quantitative PCR
In triplicate, cells stably expressing control or Ubiquilin 1
specific shRNAs were washed twice with cold PBS and
total RNA was isolated using the RNeasy Mini Kit (Qia-
gen, Inc). cDNA was synthesized using total RNA (3.5 μg),
N6 random primers (12.5 μM) and SuperScript II Reverse
Transcriptase (Invitrogen). cDNAs were diluted 1:30 using
RNase-free H2O to a final concentration of 2 ng. Diluted
cDNAs were mixed with APP or 18S primer/probe sets
(Applied Biosystems, Inc.; APP Catalog #Molecular Neurodegeneration 2007, 2:15 http://www.molecularneurodegeneration.com/content/2/1/15
Page 17 of 19
(page number not for citation purposes)
Hs00169098_m1; 18S Catalog # Hs99999901_s1), 2×
PCR Universal Master Mix (Applied Biosystems, Inc.) and
amplified using an ABI 7500 Real-Time PCR System fol-
lowing the manufacturer's directions. To determine differ-
ences in APP mRNA levels, we utilized the ΔΔCt method.
Statistical analysis
Values in the text and figures are presented as means ±
standard errors of at least three independent experiments.
Equal variance or separate variance two-sample student's
t-test were used, as appropriate, to compare two groups.
Bonferroni correction analysis was used to correct for
multiple comparisons within a single experiment.
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